MindSpire Secures New Funding from Syndicate Room for Groundbreaking Health Tech

Syndicate Room, an investment arm focusing on EIS-qualifying startups, has added MindSpire, a UK-based health technology company, to its Access EIS portfolio. Specializing in personalized vagus nerve stimulation, MindSpire aims to address chronic neurological conditions through its flagship product, SONA. MindSpire's technology leverages the vagus nerve to improve neural pathways associated with stress regulation and adaptation, offering a drug-free, non-invasive treatment option. Targeting billion-dollar markets such as stress management and chronic pain, MindSpire is poised for significant growth. With a world-class founding team, MindSpire is advancing its growth plan from pre-seed to Series A funding, with a focus on clinical trials and market expansion. Syndicate Room's investment is part of a strategy to back promising startups in the UK and offers potential substantial returns for investors.